Verona Pharma PLC
VRNA68.430USD
+2.970+4.54%
Horário de mercado （ET）Cotações atrasadas em 15 min
46.33BValor de mercado
PerdaP/L TTM
Mais detalhes de Verona Pharma PLC Empresa
Verona Pharma Plc is a United Kingdom-based biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and dual inhibitor of the enzyme’s phosphodiesterase 3 and 4 (PDE3 and PDE4) combining bronchodilator and non-steroidal anti-inflammatory activities in one compound. It is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company's wholly owned subsidiary is Verona Pharma, Inc.
Informações da empresa
Código da empresaVRNA
Nome da EmpresaVerona Pharma PLC
Data de listagemMar 30, 2005
Fundado em2005
CEODr. David S. Zaccardelli
Número de funcionários209
Tipo de títulosDepository Receipt
Fim do ano fiscalMar 30
EndereçoRiverside
CidadeLONDON
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited Kingdom
Código postalSE1 2RE
Telefone442032834200
Sitehttps://www.veronapharma.com/
Código da empresaVRNA
Data de listagemMar 30, 2005
Fundado em2005
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. David S. Zaccardelli
Dr. David S. Zaccardelli
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
11.51M
+1.80K%
Mr. Mark W. Hahn, CPA
Mr. Mark W. Hahn, CPA
Chief Financial Officer
Chief Financial Officer
10.60M
+4.02K%
Ms. Claire Louise Poll
Ms. Claire Louise Poll
General Counsel
General Counsel
541.81K
--
Mr. Vikas Sinha, CPA
Mr. Vikas Sinha, CPA
Non-Executive Independent Director
Non-Executive Independent Director
74.44K
+700.00%
Dr. Mahendra G. Shah, Ph.D.
Dr. Mahendra G. Shah, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
73.08K
+700.00%
Ms. Lisa Deschamps
Ms. Lisa Deschamps
Non-Executive Independent Director
Non-Executive Independent Director
70.32K
+700.00%
Mr. Michael Austwick
Mr. Michael Austwick
Non-Executive Director
Non-Executive Director
--
--
Dr. Kathleen Rickard, M.D.
Dr. Kathleen Rickard, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Christina Ackermann
Ms. Christina Ackermann
Non-Executive Director
Non-Executive Director
--
--
Dr. Martin William Edwards, M.D.
Dr. Martin William Edwards, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. David S. Zaccardelli
Dr. David S. Zaccardelli
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
11.51M
+1.80K%
Mr. Mark W. Hahn, CPA
Mr. Mark W. Hahn, CPA
Chief Financial Officer
Chief Financial Officer
10.60M
+4.02K%
Ms. Claire Louise Poll
Ms. Claire Louise Poll
General Counsel
General Counsel
541.81K
--
Mr. Vikas Sinha, CPA
Mr. Vikas Sinha, CPA
Non-Executive Independent Director
Non-Executive Independent Director
74.44K
+700.00%
Dr. Mahendra G. Shah, Ph.D.
Dr. Mahendra G. Shah, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
73.08K
+700.00%
Ms. Lisa Deschamps
Ms. Lisa Deschamps
Non-Executive Independent Director
Non-Executive Independent Director
70.32K
+700.00%
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Acionista
Tempo de atualização: sex, 28 de mar
Tempo de atualização: sex, 28 de mar
Estatísticas dos acionistas
Tipo
Estatísticas dos acionistas
Acionista
Proporção
Zaccardelli (David S)
13.55%
Hahn (Mark W)
12.48%
Perceptive Advisors LLC
7.52%
New Enterprise Associates (NEA)
4.81%
Frazier Life Sciences Management, L.P.
3.98%
Other
57.67%
Estatísticas dos acionistas
Acionista
Proporção
Zaccardelli (David S)
13.55%
Hahn (Mark W)
12.48%
Perceptive Advisors LLC
7.52%
New Enterprise Associates (NEA)
4.81%
Frazier Life Sciences Management, L.P.
3.98%
Other
57.67%
Tipo
Acionista
Proporção
Individual Investor
35.16%
Investment Advisor/Hedge Fund
22.11%
Hedge Fund
21.55%
Investment Advisor
15.58%
Private Equity
11.64%
Venture Capital
7.78%
Research Firm
2.44%
Family Office
1.04%
Bank and Trust
0.28%
Participação acionária institucional
Tempo de atualização: ter, 4 de mar
Tempo de atualização: ter, 4 de mar
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q1
341
98.98M
116.47%
+16.60M
2024Q4
326
71.46M
84.46%
-16.29M
2024Q3
290
72.06M
88.66%
-13.37M
2024Q2
265
71.81M
88.57%
-10.49M
2024Q1
244
72.12M
89.24%
-7.07M
2023Q4
230
69.67M
87.15%
-7.79M
2023Q3
210
67.04M
84.35%
-7.14M
2023Q2
205
65.57M
82.53%
-8.85M
2023Q1
188
68.22M
86.63%
-3.18M
2022Q4
162
65.88M
87.36%
-542.66K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Zaccardelli (David S)
11.51M
13.55%
+10.91M
+1.80K%
Mar 01, 2025
Hahn (Mark W)
10.60M
12.48%
+10.34M
+4.02K%
Mar 01, 2025
Perceptive Advisors LLC
6.39M
7.52%
+76.17K
+1.21%
Dec 31, 2024
New Enterprise Associates (NEA)
4.08M
4.81%
-1.50M
-26.86%
Jan 16, 2025
Frazier Life Sciences Management, L.P.
3.38M
3.98%
--
--
Dec 31, 2024
Ali (Behbahani)
3.19M
3.76%
+3.19M
--
Jan 16, 2025
Eventide Asset Management, LLC
3.13M
3.69%
+706.28K
+29.11%
Dec 31, 2024
Maverick Capital, Ltd.
3.13M
3.68%
-1.09M
-25.79%
Dec 31, 2024
Wellington Management Company, LLP
3.03M
3.56%
+1.15M
+61.03%
Dec 31, 2024
Vivo Capital, LLC
2.28M
2.69%
-1.27M
-35.66%
Dec 31, 2024
Ver Mais
ETFs Relacionados
Tempo de atualização: dom, 6 de abr
Tempo de atualização: dom, 6 de abr
Nome
Proporção
AdvisorShares Dorsey Wright ADR ETF
6.2%
ALPS Medical Breakthroughs ETF
4.7%
ProShares Ultra Nasdaq Biotechnology
0.5%
First Trust IPOX Europe Equity Opportunities ETF
0.49%
Invesco Nasdaq Biotechnology ETF
0.49%
iShares Biotechnology ETF
0.3%
Goldman Sachs Innovate Equity ETF
0.16%
Eventide US Market ETF
0.09%
Fidelity Nasdaq Composite Index ETF
0.01%
First Trust Long/Short Equity ETF
0%
Ver Mais
AdvisorShares Dorsey Wright ADR ETF
Proporção6.2%
ALPS Medical Breakthroughs ETF
Proporção4.7%
ProShares Ultra Nasdaq Biotechnology
Proporção0.5%
First Trust IPOX Europe Equity Opportunities ETF
Proporção0.49%
Invesco Nasdaq Biotechnology ETF
Proporção0.49%
iShares Biotechnology ETF
Proporção0.3%
Goldman Sachs Innovate Equity ETF
Proporção0.16%
Eventide US Market ETF
Proporção0.09%
Fidelity Nasdaq Composite Index ETF
Proporção0.01%
First Trust Long/Short Equity ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados